Neurocrine's movement disorder treatment fails late-stage trial
Dec 22, 2025, 5:01 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The failure of a drug in a late-stage trial significantly decreases investor confidence and can lead to stock price drops. Historical examples, such as the case with other biotech companies like Anebulo Pharmaceuticals, demonstrate significant declines post-clinical trial failures.
AI summary
What happened, with direct paths to the underlying reporting
Neurocrine's drug failed in a late-stage clinical trial for muscle control disorder.
Neurocrine's drug failed in a late-stage clinical trial for muscle control disorder.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Experts in Prader-Willi Syndrome raised safety concerns about Neurocrine's Vykat XR, citing serious adverse events in patients with the disorder. The development could create near…
Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for $53 per share, a transaction valued at $2.9 billion. This acquisition includes VYKAT XR, the only F…
Neurocrine Biosciences reported fourth-quarter adjusted earnings of $1.88, slightly below analysts' expectations of $1.89. This small miss may signal potential challenges in reven…
NBIX's valbenazine trial did not meet primary efficacy endpoints. The study focused on improving chorea in dyskinetic cerebral palsy. Analysts stated the results are disappointing…
